210 related articles for article (PubMed ID: 31819055)
1. ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry.
Wang L; Tan TK; Durbin AD; Zimmerman MW; Abraham BJ; Tan SH; Ngoc PCT; Weichert-Leahey N; Akahane K; Lawton LN; Rokita JL; Maris JM; Young RA; Look AT; Sanda T
Nat Commun; 2019 Dec; 10(1):5622. PubMed ID: 31819055
[TBL] [Abstract][Full Text] [Related]
2. LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis.
Zhu S; Zhang X; Weichert-Leahey N; Dong Z; Zhang C; Lopez G; Tao T; He S; Wood AC; Oldridge D; Ung CY; van Ree JH; Khan A; Salazar BM; Lummertz da Rocha E; Zimmerman MW; Guo F; Cao H; Hou X; Weroha SJ; Perez-Atayde AR; Neuberg DS; Meves A; McNiven MA; van Deursen JM; Li H; Maris JM; Look AT
Cancer Cell; 2017 Sep; 32(3):310-323.e5. PubMed ID: 28867147
[TBL] [Abstract][Full Text] [Related]
3. FGF represses metastasis of neuroblastoma regulated by MYCN and TGF-β1 induced LMO1 via control of let-7 expression.
Wang XH; Wu HY; Gao J; Wang XH; Gao TH; Zhang SF
Brain Res; 2019 Feb; 1704():219-228. PubMed ID: 30321496
[TBL] [Abstract][Full Text] [Related]
4. Collaborative ISL1/GATA3 interaction in controlling neuroblastoma oncogenic pathways overlapping with but distinct from MYCN.
Zhang Q; Zhang Q; Jiang X; Ye Y; Liao H; Zhu F; Yan J; Luo L; Tian L; Jiang C; Chen Y; Liang X; Sun Y
Theranostics; 2019; 9(4):986-1000. PubMed ID: 30867811
[No Abstract] [Full Text] [Related]
5. ASCL1 characterizes adrenergic neuroblastoma via its pioneer function and cooperation with core regulatory circuit factors.
Wang L; Tan TK; Kim H; Kappei D; Tan SH; Look AT; Sanda T
Cell Rep; 2023 Dec; 42(12):113541. PubMed ID: 38060444
[TBL] [Abstract][Full Text] [Related]
6. HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype.
Xu M; Sun M; Zhang X; Nguyen R; Lei H; Shern JF; Thiele CJ; Liu Z
Cancer Res; 2023 Mar; 83(5):686-699. PubMed ID: 36598365
[TBL] [Abstract][Full Text] [Related]
7. Back to the future: evolutionary biology reveals a key regulatory switch in neuroblastoma pathogenesis.
Wertman JN; Berman JN
J Clin Invest; 2023 May; 133(10):. PubMed ID: 37183823
[TBL] [Abstract][Full Text] [Related]
8. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry.
Durbin AD; Zimmerman MW; Dharia NV; Abraham BJ; Iniguez AB; Weichert-Leahey N; He S; Krill-Burger JM; Root DE; Vazquez F; Tsherniak A; Hahn WC; Golub TR; Young RA; Look AT; Stegmaier K
Nat Genet; 2018 Sep; 50(9):1240-1246. PubMed ID: 30127528
[TBL] [Abstract][Full Text] [Related]
9. Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.
Rajbhandari P; Lopez G; Capdevila C; Salvatori B; Yu J; Rodriguez-Barrueco R; Martinez D; Yarmarkovich M; Weichert-Leahey N; Abraham BJ; Alvarez MJ; Iyer A; Harenza JL; Oldridge D; De Preter K; Koster J; Asgharzadeh S; Seeger RC; Wei JS; Khan J; Vandesompele J; Mestdagh P; Versteeg R; Look AT; Young RA; Iavarone A; Lasorella A; Silva JM; Maris JM; Califano A
Cancer Discov; 2018 May; 8(5):582-599. PubMed ID: 29510988
[TBL] [Abstract][Full Text] [Related]
10. The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression.
Zhao Z; Shelton SD; Oviedo A; Baker AL; Bryant CP; Omidvarnia S; Du L
J Exp Clin Cancer Res; 2020 Feb; 39(1):41. PubMed ID: 32087738
[TBL] [Abstract][Full Text] [Related]
11. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.
Hsu CL; Chang HY; Chang JY; Hsu WM; Huang HC; Juan HF
Oncotarget; 2016 Jun; 7(24):36293-36310. PubMed ID: 27167114
[TBL] [Abstract][Full Text] [Related]
12. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets.
Decaesteker B; Denecker G; Van Neste C; Dolman EM; Van Loocke W; Gartlgruber M; Nunes C; De Vloed F; Depuydt P; Verboom K; Rombaut D; Loontiens S; De Wyn J; Kholosy WM; Koopmans B; Essing AHW; Herrmann C; Dreidax D; Durinck K; Deforce D; Van Nieuwerburgh F; Henssen A; Versteeg R; Boeva V; Schleiermacher G; van Nes J; Mestdagh P; Vanhauwaert S; Schulte JH; Westermann F; Molenaar JJ; De Preter K; Speleman F
Nat Commun; 2018 Nov; 9(1):4866. PubMed ID: 30451831
[TBL] [Abstract][Full Text] [Related]
13. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
[TBL] [Abstract][Full Text] [Related]
14. Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism.
Oldridge DA; Wood AC; Weichert-Leahey N; Crimmins I; Sussman R; Winter C; McDaniel LD; Diamond M; Hart LS; Zhu S; Durbin AD; Abraham BJ; Anders L; Tian L; Zhang S; Wei JS; Khan J; Bramlett K; Rahman N; Capasso M; Iolascon A; Gerhard DS; Guidry Auvil JM; Young RA; Hakonarson H; Diskin SJ; Look AT; Maris JM
Nature; 2015 Dec; 528(7582):418-21. PubMed ID: 26560027
[TBL] [Abstract][Full Text] [Related]
15. Dephosphorylation of the Proneural Transcription Factor ASCL1 Re-Engages a Latent Post-Mitotic Differentiation Program in Neuroblastoma.
Ali FR; Marcos D; Chernukhin I; Woods LM; Parkinson LM; Wylie LA; Papkovskaia TD; Davies JD; Carroll JS; Philpott A
Mol Cancer Res; 2020 Dec; 18(12):1759-1766. PubMed ID: 33046535
[TBL] [Abstract][Full Text] [Related]
16. Chromatin Immunoprecipitation and DNA Sequencing Identified a LIMS1/ILK Pathway Regulated by LMO1 in Neuroblastoma.
Saeki N; Saito A; Sugaya Y; Amemiya M; Ono H; Komatsuzaki R; Yanagihara K; Sasaki H
Cancer Genomics Proteomics; 2018; 15(3):165-174. PubMed ID: 29695398
[TBL] [Abstract][Full Text] [Related]
17. Integrative genomics identifies LMO1 as a neuroblastoma oncogene.
Wang K; Diskin SJ; Zhang H; Attiyeh EF; Winter C; Hou C; Schnepp RW; Diamond M; Bosse K; Mayes PA; Glessner J; Kim C; Frackelton E; Garris M; Wang Q; Glaberson W; Chiavacci R; Nguyen L; Jagannathan J; Saeki N; Sasaki H; Grant SF; Iolascon A; Mosse YP; Cole KA; Li H; Devoto M; McGrady PW; London WB; Capasso M; Rahman N; Hakonarson H; Maris JM
Nature; 2011 Jan; 469(7329):216-20. PubMed ID: 21124317
[TBL] [Abstract][Full Text] [Related]
18. SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma.
Tan K; Mo J; Li M; Dong Y; Han Y; Sun X; Ma Y; Zhu K; Wu W; Lu L; Liu J; Zhao K; Zhang L; Tang Y; Lv Z
J Exp Clin Cancer Res; 2022 Dec; 41(1):352. PubMed ID: 36539767
[TBL] [Abstract][Full Text] [Related]
19. Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.
Smith AG; Popov N; Imreh M; Axelson H; Henriksson M
J Cell Biochem; 2004 Aug; 92(6):1282-95. PubMed ID: 15258910
[TBL] [Abstract][Full Text] [Related]
20. Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.
Duffy DJ; Krstic A; Halasz M; Schwarzl T; Konietzny A; Iljin K; Higgins DG; Kolch W
Genome Med; 2017 Feb; 9(1):15. PubMed ID: 28187790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]